European journal of cancer
Journal
Overview
publication venue for
-
Corrigendum to "International expert consensus on the clinical integration of circulating tumor cells in solid tumors" [Eur. J. Cancer 231 (2025) 116050].
2025
-
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients..
214.
2024
-
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study..
213.
2024
-
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials..
207.
2024
-
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00..
200.
2024
-
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients..
199.
2024
-
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects..
199.
2023
-
Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance..
197.
2023
-
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations..
196.
2023
-
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response..
195.
2023
-
Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression..
195.
2023
-
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study..
192.
2023
-
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition..
189.
2023
-
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases..
185.
2023
-
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study..
169.
2022
-
The regulation of CD73 in non-small cell lung cancer..
170.
2022
-
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer..
169.
2022
-
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment..
168.
2022
-
Evolution of low HER2 expression between early and advanced-stage breast cancer..
163.
2022
-
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006..
157.
2021
-
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice..
157.
2021
-
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour..
155.
2021
-
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer..
150.
2021
-
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy..
149.
2021
-
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study..
146.
2021
-
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma..
144.
2020
-
Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways..
144.
2020
-
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma..
135.
2020
-
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer..
135.
2020
-
Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..
133.
2020
-
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative..
130.
2020
-
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma..
126.
2020
-
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials..
125.
2020
-
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours..
120.
2019
-
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial..
119.
2019
-
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial..
114.
2019
-
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors..
114.
2019
-
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort..
109.
2019
-
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study..
109.
2019
-
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT..
96.
2018
-
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update..
94.
2018
-
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study..
94.
2018
-
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma..
90.
2018
-
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma..
89.
2017
-
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma..
86.
2017
-
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma..
86.
2017
-
Menopausal hormone therapy and cancer risk: An overestimated risk?.
84.
2017
-
Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis..
63.
2016
-
Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours..
59.
2016
-
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas..
51.
2015
-
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies..
51.
2015
-
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer..
51.
2015
-
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression..
51.
2015
-
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib..
51.
2015
-
Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors..
51.
2014
-
Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma..
51.
2014
-
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events..
50.
2014
-
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma..
50.
2014
-
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials..
50.
2013
-
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report..
49.
2013
-
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer..
49.
2012
-
Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours..
48.
2012
-
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas..
48.
2012
-
Long term renal toxicity of ifosfamide in adult patients--5 year data..
48.
2012
-
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study..
48.
2012
-
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study..
48.
2011
-
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study..
47.
2011
-
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma..
47.
2010
-
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib..
46.
2010
-
Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study..
46.
2010
-
Management and outcome of stage 3 neuroblastoma..
45.
2008
-
Management of malignant bowel obstruction..
44.
2008
-
UbcH10 is overexpressed in malignant breast carcinomas..
43.
2007
-
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma..
43.
2007
-
Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck..
41.
2005
-
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose..
40.
2004
-
Studies with cytotoxic agents suggest that apoptosis is not a major determinant of clonogenic death in neuroblastoma cells..
39.
2003
-
Does use of alternative medicine predict survival from cancer?.
39.
2003
-
Tamoxifen for primary breast cancer prevention in BRCA heterozygotes..
38 Suppl 6.
2002
-
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract..
36 Suppl 2.
2000
-
Prevalence of complementary therapy use by women with breast cancer. A population-based survey..
36.
2000
-
Radiotherapy of the brain in elderly patients. arbiter:.
36.
2000
-
Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice..
36.
2000
-
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast..
33.
1997
-
Phase II study of semisynthetic paclitaxel in metastatic breast cancer..
33.
1997
-
Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma..
33.
1997
-
Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma..
33.
1997
-
Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers..
33.
1997
-
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma..
33.
1997
-
High-dose chemotherapy of breast cancer: current status and developmental strategies..
31A.
1995
-
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma..
30A.
1994
-
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress..
30A.
1994
-
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS)..
29A Suppl 1.
1993
-
Effects of extracellular matrix on the response of endothelial cells to radiation in vitro..
28A.
1992
-
Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines..
27.
1991
-
Haemodynamic effects of recombinant interleukin-2 administered by constant infusion..
27.
1991
-
Unusual clonal evolution during blast crisis of chronic myeloid leukaemia (CML).
30A.
1994
-
Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".
2022
-
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
2019
-
Comment on: Does use of alternative medicine predict survival from cancer? Eur J Cancer 2003, 39, 372-377.
2003
-
Magnetic resonance imaging in breast cancer: is seeing always believing?.
41.
2005
-
Continued refinement in the treatment of germ cell tumour patients..
27.
1991
-
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.
2020
-
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
2014
-
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
2025
-
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
2022
-
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
2020
-
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
2017
-
The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
2017
-
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
2016
-
Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.
2015
-
International expert opinion on patient-tailored management of soft tissue sarcomas.
2013
-
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
2011
-
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
2011
-
Small animal imaging. current technology and perspectives for oncological imaging.
2002
-
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
1996
-
International expert consensus on the clinical integration of circulating tumor cells in solid tumors.
2025
-
Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
2021
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)